Acute hematological toxicity during post-operative bowel sparing image-guided intensity modulated radiation with concurrent cisplatin
- PMID: 30179056
- PMCID: PMC6319830
- DOI: 10.1259/bjr.20180005
Acute hematological toxicity during post-operative bowel sparing image-guided intensity modulated radiation with concurrent cisplatin
Abstract
Objective: To report acute hematological toxicity (HT) in patients receiving post-operative bowel sparing intensity-modulated radiotherapy (IMRT) and cisplatin and its dosimetric predictors.
Methods: Clinical database of Phase III trial (NCT01279135), that randomized patients to post-operative conformal or intensity modulated radiation therapy, was searched to select patient strata that received bowel sparing IMRT (50 Gy/25#/5 wks) and concurrent cisplatin (40 mg m-2). Pelvic bone marrow (BM) was retrospectively delineated in two sets: whole bone (WB), and freehand (FH) inner cavity of bone. Dose volume histograms (DVH) of BM were obtained. Receiver operating characteristic (ROC) curve identified DVH thresholds that predicted for Grade≥ II HT with highest specificity. Univariate and multivariate analysis was performed.
Results: Overall 75 patients received concurrent cisplatin. Grades I-V HT was observed in 38.7%, 42.7%, 14.7%, 0%, and 0% patients, respectively. Grade ≥ II leukopenia, neutropenia, anemia, and thrombocytopenia were observed in 26%, 40%, 26.5%, and 1.4% respectively. None of the HT resulted in treatment break. On univariate analysis, whole pelvis+ lumbar FH V30 >55% & V40>35%, whole pelvis WB and FH V40 > 35%, and lower pelvis WB and FH V40 >20% correlated for Grade ≥ II leucopenia and neutropenia. None of the BM dose volume constraints predicted for overall HT or neutropenia on multivariate analysis.
Conclusion: The IMRT arm of NCT01279135 (PARCER study) that employed strict bowel constraints had unintentional but desirable BM sparing. None of the BM subvolume DVH parameters could be validated on multivariate analysis.
Advances in knowledge: The prospective study reports feasibility of bone marrow sparing with bowel sparing post-operative pelvic IMRT and concurrent chemotherapy for cervical cancer. The present study reports low incidence of hematological and gastrointestinal toxicity during post-operative chemoradiation with IMRT. As both whole bone and freehand pelvis BM contours predicted for HT, hence an easier method of whole bone contouring should continue to be used till further validation of more specific BM subvolumes becomes available. The study results highlight the need for further research into dose volume constraints during post-operative IMRT.
Similar articles
-
Comparison of 2 contouring methods of bone marrow on CT and correlation with hematological toxicities in non-bone marrow-sparing pelvic intensity-modulated radiotherapy with concurrent cisplatin for cervical cancer.Int J Gynecol Cancer. 2012 Oct;22(8):1427-34. doi: 10.1097/IGC.0b013e3182664b46. Int J Gynecol Cancer. 2012. PMID: 22932264 Clinical Trial.
-
Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy.Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1356-65. doi: 10.1016/j.ijrobp.2006.03.018. Epub 2006 Jun 6. Int J Radiat Oncol Biol Phys. 2006. PMID: 16757127
-
Association between bone marrow dosimetric parameters and acute hematologic toxicity in cervical cancer patients undergoing concurrent chemoradiotherapy: comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy.Int J Gynecol Cancer. 2014 Nov;24(9):1648-52. doi: 10.1097/IGC.0000000000000292. Int J Gynecol Cancer. 2014. PMID: 25275663 Free PMC article.
-
Pelvic bone marrow sparing radiotherapy for cervical cancer: A systematic review and meta-analysis.Radiother Oncol. 2021 Dec;165:103-118. doi: 10.1016/j.radonc.2021.10.015. Epub 2021 Oct 27. Radiother Oncol. 2021. PMID: 34718055
-
Whole pelvic intensity-modulated radiotherapy for gynecological malignancies: A review of the literature.Crit Rev Oncol Hematol. 2015 Jun;94(3):371-9. doi: 10.1016/j.critrevonc.2014.12.015. Epub 2015 Jan 3. Crit Rev Oncol Hematol. 2015. PMID: 25600840 Free PMC article. Review.
Cited by
-
Contribution of Tata Memorial Centre, India, to cervical cancer care: Journey of two decades.Indian J Med Res. 2021 Aug;154(2):319-328. doi: 10.4103/ijmr.IJMR_339_21. Indian J Med Res. 2021. PMID: 35295006 Free PMC article. Review.
-
Synergistic or Additive Pharmacological Interactions between Magnoflorine and Cisplatin in Human Cancer Cells of Different Histological Origin.Int J Mol Sci. 2020 Apr 19;21(8):2848. doi: 10.3390/ijms21082848. Int J Mol Sci. 2020. PMID: 32325867 Free PMC article.
-
Dose escalation of tolinapant (ASTX660) in combination with standard radical chemoradiotherapy in cervical cancer : a study protocol for a phase 1b TiTE-CRM clinical trial (CRAIN) in UK secondary care centres.BMC Cancer. 2024 Jun 7;24(1):702. doi: 10.1186/s12885-024-12310-w. BMC Cancer. 2024. PMID: 38849715 Free PMC article.
-
Hematologic Toxicity and Bone Marrow-Sparing Strategies in Chemoradiation for Locally Advanced Cervical Cancer: A Systematic Review.Cancers (Basel). 2024 May 11;16(10):1842. doi: 10.3390/cancers16101842. Cancers (Basel). 2024. PMID: 38791920 Free PMC article. Review.
-
A prospective single-arm study on the relationship between dose-volume parameters of pelvic functional bone marrow and acute hematological toxicities during intensity-modulated radiotherapy with or without concurrent chemotherapy for uterine cervical/endometrial cancer.Radiat Oncol. 2023 Nov 27;18(1):193. doi: 10.1186/s13014-023-02380-8. Radiat Oncol. 2023. PMID: 38012675 Free PMC article.
References
-
- Peters WA, Liu PY, Barrett RJ, Stock RJ, Monk BJ, Berek JS, et al. . (eds) Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18: 1606–13. doi: 10.1200/JCO.2000.18.8.1606 - DOI - PubMed
-
- Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study. Gynecol Oncol 1999; 73: 177–83. doi: 10.1006/gyno.1999.5387 - DOI - PubMed
-
- Rotman M, Sedlis A, Piedmonte MR, Bundy B, Lentz SS, Muderspach LI, et al. . A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. International journal of radiation oncology, biology. Physics 2006; 65: 169–76. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous